Centrum Broking's research report on MRPL
We retain BUY on MRPL, with a revised TP of Rs 97. The company reported robust GRM of USD10.0/bbl vs USD8.2/bbl in Q4FY16. However, on adjusting it for inventory gains, the core GRM was at USD5.4/bbl vs benchmark Singapore GRM of USD5.0/bbl. Core GRM could have been higher, but owing to state’s restriction on use of water led to momentary dip in throughput and lower distillate yield. Currently, MRPL has indicated a core GRM of USD5/bbl in Q2FY17 until August at a premium to benchmark Singapore GRM of USD4/bbl, and it remains resilient owing to GRM accretive Petchem operations. MRPL is a strong investment bet, with phase-III commissioned, integration of OMPL underway, positive turnaround in earnings and valuation discount to global peers, all of which cap the downside.For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!